Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 2 Bromo Alpha Ergocryptine
2. 2 Bromo Alpha Ergokryptine
3. 2 Bromoergocryptine
4. 2 Bromoergocryptine Mesylate
5. 2 Bromoergocryptine Methanesulfonate
6. 2 Bromoergokryptine
7. 2-bromo-alpha-ergocryptine
8. 2-bromo-alpha-ergokryptine
9. 2-bromoergocryptine
10. 2-bromoergocryptine Mesylate
11. 2-bromoergocryptine Methanesulfonate
12. 2-bromoergokryptine
13. Bromocriptin
14. Bromocriptine
15. Bromocryptin
16. Cb 154
17. Cb-154
18. Cb154
19. Mesylate, 2-bromoergocryptine
20. Mesylate, Bromocriptine
21. Methanesulfonate, 2-bromoergocryptine
22. Parlodel
1. 22260-51-1
2. Parlodel
3. Bromocriptine Mesilate
4. Bromocryptine Mesylate
5. Pravidel
6. Bromocriptine Methanesulfonate
7. Cycloset
8. Bagren
9. Cb-154 Mesylate
10. Bromergon
11. (+)-bromocriptine Methanesulfonate
12. 2-bromo-alpha-ergocryptine Mesylate
13. Cb-154
14. Cb-154 Mesilate
15. Cb 154
16. 2-bromoergocryptine Monomethanesulfonate (salt)
17. Ffp983j3od
18. Bromocriptine (mesylate)
19. Chebi:3182
20. 2-bromoergocryptine Mesylate
21. Nsc-755915
22. Oline-9-carboxamide Methanesulfonate
23. Bromocryptine Methanesulfonate
24. (5'a)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Mesylate
25. Bromocriptine Mesylate [usan]
26. Nsc169774
27. Sr-01000597796
28. Einecs 244-881-1
29. Unii-ffp983j3od
30. 2-bromo-alpha-ergocryptine Methanesulfonate
31. Sr-01000075356
32. 2-bromine-alpha-ergocryptine Methanesulfonate
33. 2-bromo-alpha-ergokryptine-mesilate [german]
34. Bromocriptine Mesylate [usan:usp]
35. Parlodel (tn)
36. (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman Methanesulfonate (salt)
37. (6ar,9r)-5-bromo-n-[(2r,5s,10as,10bs)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8h-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quin
38. 2-bromo-alpha-ergokryptine-mesilate
39. Prestwick_771
40. Cas-22260-51-1
41. Dsstox_cid_197
42. Bromocriptinemesylate
43. Alpha-ergocryptine, 2-bromo-, Methanesulfonate
44. Dsstox_rid_75426
45. Dsstox_gsid_20197
46. Schembl40559
47. 2-bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione Monomethanesulphonate
48. Bromocriptine Mesylate (usp)
49. Bromocriptine Mesylate- Bio-x
50. Bromocriptine Mesilate (jp17)
51. Chembl1200503
52. Dtxsid6020197
53. 2-bromo ?-ergocryptine Mesylate
54. Cb 154 Methanesulfonate (salt)
55. C32h40brn5o5.ch3so3h
56. Hms1568i04
57. Hms3260d03
58. Hms3411k09
59. Hms3675k09
60. Hms3712i04
61. 2-bromo Alpha-ergocryptine Mesylate
62. Bromocriptine Mesilate [jan]
63. Tox21_303597
64. Tox21_500171
65. Hy-12705a
66. Bromocriptine Mesylate [vandf]
67. .alpha.-ergocryptine, Methanesulfonate
68. Akos015896276
69. Bromocriptine Mesilate [mart.]
70. Bromocriptine Mesilate [who-dd]
71. Bromocriptine Mesylate [usp-rs]
72. Ccg-220121
73. Ccg-221475
74. Cs-6048
75. Lp00171
76. Nsc 755915
77. Nsc-169774
78. Ncgc00257268-01
79. Ncgc00260856-01
80. Bb164266
81. Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, Monomethanesulfonate (salt), (5'alpha)-
82. Bromocriptine Methanesulfonate [mi]
83. Bromocriptine Mesylate [orange Book]
84. 2-bromo-a-ergocryptine Methanesulfonate Salt
85. B6298
86. Bromocriptine Mesilate [ep Monograph]
87. Eu-0100171
88. Bromocriptine Mesylate [usp Monograph]
89. B 2134
90. D00780
91. D81822
92. 2-bromo-.alpha.-ergocryptine Monomethanesulfonate
93. A903911
94. Sr-01000075356-1
95. Sr-01000597796-1
96. Sr-01000597796-2
97. Q27105974
98. 2-bromoergocryptine Monomethanesulphonate (salt)
99. (+)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6'-18-trione Methanesulfonate Salt
100. (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman Methanesulfonate
101. (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman Methanesulfonate
102. (6ar,9r)-5-bromo-n-[(1s,2s,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic Acid
103. Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5.alpha.)-, Methanesulfonate (1:1)
104. Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, Monomethanesulfonate (salt), (5'.alpha.)-
105. Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, Monomethanesulphonate (salt), (5'.alpha.)-
Molecular Weight | 750.7 g/mol |
---|---|
Molecular Formula | C33H44BrN5O8S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 5 |
Exact Mass | 749.20940 g/mol |
Monoisotopic Mass | 749.20940 g/mol |
Topological Polar Surface Area | 181 Ų |
Heavy Atom Count | 48 |
Formal Charge | 0 |
Complexity | 1320 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Bromocriptine mesylate |
Drug Label | Bromocriptine mesylate is an ergot derivative with potent dopamine receptor agonist activity. Each bromocriptine mesylate tablet, USP for oral administration contains 2.5 mg bromocriptine (as the mesylate). Bromocriptine mesylate is chemically design... |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 5mg base; eq 2.5mg base |
Market Status | Prescription |
Company | Lek Pharms; Paddock; Zydus Pharms Usa; Mylan |
2 of 6 | |
---|---|
Drug Name | Cycloset |
PubMed Health | Bromocriptine (By mouth) |
Drug Classes | Antidiabetic, Antiparkinsonian, Prolactin Secretion Inhibitor |
Drug Label | CYCLOSET Tablets contain bromocriptine mesylate, a dopamine receptor agonist. Bromocriptine mesylate is chemically designated [Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulf |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.8mg base |
Market Status | Prescription |
Company | Veroscience |
3 of 6 | |
---|---|
Drug Name | Parlodel |
PubMed Health | Bromocriptine (By mouth) |
Drug Classes | Antidiabetic, Antiparkinsonian, Prolactin Secretion Inhibitor |
Drug Label | Parlodel (bromocriptine mesylate) is an ergot derivative with potent dopamine receptor agonist activity. Each Parlodel (bromocriptine mesylate) SnapTabs tablet for oral administration contains 2 mg and each capsule contains 5 mg bromocriptine... |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 5mg base; eq 2.5mg base |
Market Status | Prescription |
Company | Us Pharms Holdings I |
4 of 6 | |
---|---|
Drug Name | Bromocriptine mesylate |
Drug Label | Bromocriptine mesylate is an ergot derivative with potent dopamine receptor agonist activity. Each bromocriptine mesylate tablet, USP for oral administration contains 2.5 mg bromocriptine (as the mesylate). Bromocriptine mesylate is chemically design... |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 5mg base; eq 2.5mg base |
Market Status | Prescription |
Company | Lek Pharms; Paddock; Zydus Pharms Usa; Mylan |
5 of 6 | |
---|---|
Drug Name | Cycloset |
PubMed Health | Bromocriptine (By mouth) |
Drug Classes | Antidiabetic, Antiparkinsonian, Prolactin Secretion Inhibitor |
Drug Label | CYCLOSET Tablets contain bromocriptine mesylate, a dopamine receptor agonist. Bromocriptine mesylate is chemically designated [Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulf |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.8mg base |
Market Status | Prescription |
Company | Veroscience |
6 of 6 | |
---|---|
Drug Name | Parlodel |
PubMed Health | Bromocriptine (By mouth) |
Drug Classes | Antidiabetic, Antiparkinsonian, Prolactin Secretion Inhibitor |
Drug Label | Parlodel (bromocriptine mesylate) is an ergot derivative with potent dopamine receptor agonist activity. Each Parlodel (bromocriptine mesylate) SnapTabs tablet for oral administration contains 2 mg and each capsule contains 5 mg bromocriptine... |
Active Ingredient | Bromocriptine mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 5mg base; eq 2.5mg base |
Market Status | Prescription |
Company | Us Pharms Holdings I |
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Hormone Antagonists
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Bromocriptine Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bromocriptine Mesylate, including repackagers and relabelers. The FDA regulates Bromocriptine Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bromocriptine Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bromocriptine Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bromocriptine Mesylate supplier is an individual or a company that provides Bromocriptine Mesylate active pharmaceutical ingredient (API) or Bromocriptine Mesylate finished formulations upon request. The Bromocriptine Mesylate suppliers may include Bromocriptine Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Bromocriptine Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bromocriptine Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bromocriptine Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Bromocriptine Mesylate DMFs exist exist since differing nations have different regulations, such as Bromocriptine Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bromocriptine Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Bromocriptine Mesylate USDMF includes data on Bromocriptine Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bromocriptine Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bromocriptine Mesylate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bromocriptine Mesylate Drug Master File in Japan (Bromocriptine Mesylate JDMF) empowers Bromocriptine Mesylate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bromocriptine Mesylate JDMF during the approval evaluation for pharmaceutical products. At the time of Bromocriptine Mesylate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bromocriptine Mesylate suppliers with JDMF on PharmaCompass.
A Bromocriptine Mesylate CEP of the European Pharmacopoeia monograph is often referred to as a Bromocriptine Mesylate Certificate of Suitability (COS). The purpose of a Bromocriptine Mesylate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Bromocriptine Mesylate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Bromocriptine Mesylate to their clients by showing that a Bromocriptine Mesylate CEP has been issued for it. The manufacturer submits a Bromocriptine Mesylate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Bromocriptine Mesylate CEP holder for the record. Additionally, the data presented in the Bromocriptine Mesylate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Bromocriptine Mesylate DMF.
A Bromocriptine Mesylate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Bromocriptine Mesylate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Bromocriptine Mesylate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bromocriptine Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bromocriptine Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bromocriptine Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bromocriptine Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bromocriptine Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bromocriptine Mesylate suppliers with NDC on PharmaCompass.
Bromocriptine Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bromocriptine Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bromocriptine Mesylate GMP manufacturer or Bromocriptine Mesylate GMP API supplier for your needs.
A Bromocriptine Mesylate CoA (Certificate of Analysis) is a formal document that attests to Bromocriptine Mesylate's compliance with Bromocriptine Mesylate specifications and serves as a tool for batch-level quality control.
Bromocriptine Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Bromocriptine Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bromocriptine Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bromocriptine Mesylate EP), Bromocriptine Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bromocriptine Mesylate USP).
LOOKING FOR A SUPPLIER?